1 Varela E, Blasco M A. 2009 Nobel prize in physiology or medicine: telomeres and telomerase. Oncogene, 2010, 29: 1561-1565
[2]
2 Kirkpatrick K L, Mokbel K. The significance of human telomerase reverse transcriptase (hTERT) in cancer. Eur J Surg Oncol, 2001, 27: 754-760
[3]
3 Xu L, Li S, Stohr B A. The role of telomere biology in cancer. Annu Rev Pathol, 2013, 8: 49-78
[4]
4 Huang F W, Hodis E, Xu M J, et al. Highly recurrent TERT promoter mutations in human melanoma. Science, 2013, 339: 957-959
[5]
5 Horn S, Figl A, Rachakonda P S, et al. TERT promoter mutations in familial and sporadic melanoma. Science, 2013, 339: 959-961
[6]
6 Killela P J, Reitman Z J, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA, 2013, 110: 6021-6026
[7]
7 Quaas A, Oldopp T, Tharun L, et al. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch, 2014, 465: 673-677
[8]
8 Rachakonda P S, Hosen I, de Verdier P J, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA, 2013, 110: 17426-17431
[9]
9 Wu S, Huang P, Li C, et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol, 2014, 65: 274-277
[10]
10 Melo M, da Rocha A G, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab, 2014, 99: E754-E765
[11]
11 Wu RC, Ayhan A, Maeda D, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol, 2014, 232: 473-481
[12]
12 Hosen I, Rachakonda P S, Heidenreich B, et al. TERT promoter mutations in clear cell renal cell carcinoma. Int J Cancer, 2015, 136: 2448-2452
[13]
13 Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun, 2013, 4: 2185
[14]
14 Heidenreich B, Rachakonda P S, Hemminki K, et al. TERT promoter mutations in cancer development. Curr Opin Genet Dev, 2014, 24: 30-37
[15]
15 Borah S, Xi L, Zaug A J, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science, 2015, 347: 1006-1010
[16]
16 Huang D S, Wang Z, He X J, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer, 2015, 51: 969-976
[17]
17 Bell R J, Rube H T, Kreig A, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science, 2015, 348: 1036-1039
[18]
18 Vinagre J, Pinto V, Celestino R, et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch, 2014, 465: 119-133
[19]
19 Liu Y, Zeng Y, Liu L, et al. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat Commun, 2014, 5: 5393
[20]
20 Liu Z, Li Q, Li K, et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene, 2013, 32: 4203-4213
